Better Health for All

Zoetis's core business delivers revolutionary health benefits by focusing 100% of its $686 million R&D budget in 2024 on animal health, which significantly impacts human health through zoonotic disease prevention and global food security.

The company maintains a perfect safety record with no product-related fatalities. Zoetis generates 10% of its 2024 revenue from livestock antibiotics, but is actively partnering to reduce antibiotic dependency. The company demonstrates substantial positive health externalities through initiatives like A.L.P.H.A. Plus, which has treated 16.7 million cows and 354.9 million chickens in Sub-Saharan Africa, improving livelihoods. Zoetis provides exceptional support for the healthcare workforce, including nearly 500 veterinary student scholarships, 150+ vet tech scholarships, and 75,766 trainings for professionals and farmers since 2019. , , It also implements exceptional mental health programs for veterinary professionals and rural communities, and exceptional healthcare education initiatives. However, the Zoetis Foundation's grants and corporate giving for health equity programs totaled $20.2 million in 2024, representing 0.217% of its $9.3 billion revenue, which is considered minimal.

Fair Money & Economic Opportunity

Zoetis Inc. is an animal health company, not a financial institution. As such, most KPIs related to financial products, lending, fees, debt, and banking access points are not applicable, resulting in a score of 0. For profit reinvestment, Zoetis invested $20.2 million in community initiatives and grants in 2024.

This represents approximately 0.81% of its 2024 net income of $2,486 million, which falls into the -90 tier. While Zoetis's A.L.P.H.A. Plus initiative trains farmers and aims to enhance livelihoods in underserved regions, the articles do not provide the specific percentage of total customers from these segments or measurable financial outcomes like credit score increases or savings growth, preventing a score for underserved_client_share and wealth_building_outcome.

Fair Pay & Worker Respect

Zoetis conducts regular pay equity analyses, with a 2022 external third-party analysis finding no indicators of systemic discrimination in its compensation program

. However, a 2024 lawsuit claims the company based male employees' pay on previous salaries, a practice that can perpetuate the gender pay gap . Separately, a 2021 lawsuit alleging a former employee was paid less than male counterparts was dismissed by the court .

Fair Trade & Ethical Sourcing

No specific, quantifiable evidence was found in the provided articles to assess Zoetis Inc. against the defined KPIs for Fair Trade & Ethical Sourcing. The articles mention supplier conduct principles

, a conflict minerals compliance program , and initiatives to increase supply chain transparency , but do not provide data points such as percentages of certified spend, audit frequencies, number of labor incidents, traceability coverage, remediation times, ethical clause coverage in contracts, share of high-risk materials, or supplier diversity spend.

Honest & Fair Business

Zoetis incurred $231,452 in penalties for environment-related and safety-related offenses.

The company maintains a comprehensive anti-bribery and anti-corruption policy, referencing the US Foreign Corrupt Practices Act and the UK Bribery Act. In 2023, 100% of colleagues completed annual Code of Conduct training, and the compliance function conducts continuous, near real-time monitoring of colleague expenses. Zoetis also has a comprehensive whistleblower policy that prohibits retaliation and offers multiple reporting channels, including a 24/7 anonymous helpline available in 70 languages and a web portal. Potential violations are escalated to a Compliance Investigations function, and disciplinary actions are tracked.

Kind to Animals

Zoetis uses animal testing in the development and testing of its products, with no evidence of cruelty-free certification for any products.

The company has an internal program (TAFAT) to develop and validate in vitro tests as alternatives to in vivo tests, taking an "in vitro first" approach for new vaccines. This program has gained regulatory approval for non-animal release tests for one Leptospirosis vaccine and Rabies vaccines in the EU. Additionally, the VAC2VAC project, in which Zoetis played a key role, validated two in vitro assays approved as replacements for animal tests. The company's Policy on Animal Care and Welfare ensures all animal use is reviewed for scientific merit, considers the 3Rs (Replacement, Reduction, and Refinement), and is conducted ethically. This policy includes provisions for site accreditation by AAALAC and local ethical oversight committee monitoring. Site audits are conducted at least annually, and external third-party sites are audited based on risk assessments. Zoetis supported endangered species protection programs and collaborated on a global trial for an avian wildlife HPAI vaccination effort in five species from January to May 2024. The company participates in cross-industry efforts like the VAC2VAC project and is a member of the European Partnership for Alternatives to Animal Testing. Zoetis is also an active member of AnimalhealthEurope and HealthforAnimals' 3R's taskforce, focusing on animal welfare and advocating for higher standards.

No War, No Weapons

Zoetis Inc. was awarded minor contracts by the U.S. Army totaling $55,200 in 2023 and 2024 for veterinary equipment and supplies.

These products are for veterinary use and are explicitly stated as not involving weaponry or conflict facilitation. The company's core business is animal health, and there is no evidence of dual-use technology development, military AI systems, or involvement in surveillance activities. The Board of Directors receives semi-annual updates on the Enterprise Risk Management Program. Zoetis has no known defense assets requiring divestment, nor does it have a stated policy for divestment from conflict-zone exposures. There is no evidence of human rights due diligence in conflict-affected areas, Arms Trade Treaty compliance declarations, or specific ethical red lines coded to ban categories of weapons. The company does not report on war-related supply chain risk audits, annual conflict partner reviews, or procurement from conflict zones.

Planet-Friendly Business

Zoetis Inc. reported total Scope 1, 2, and 3 emissions of 169,110 tCO2e in 2024, representing a 20.65% annual decline from 2023.

The company has no SBTi-aligned targets and does not anticipate setting one in the next two years. As of 2024, 33.6% of total operational energy is sourced from renewables, with 80.6% of total Scope 2 electricity use from renewables. Water intake intensity was 268 cubic meters per $1 million revenue in 2024, with 20.8% of water intake from areas of high or extremely high water stress. The company recorded one water-related fine totaling $13,466 in 2023. Zoetis aims for carbon neutrality in its own operations by 2030, supported by a roadmap and interim transportation-related emissions reduction targets. The company aligns with TCFD in mainstream reports, includes a TCFD Index, and describes the resilience of its strategy considering climate-related scenarios, including a 2°C or lower scenario. Zoetis funds initiatives such as the American Red Cross for global disaster preparedness and relief, and the World Food Program USA and A.L.P.H.A. Plus to enhance farmer livelihoods and access to veterinary services in vulnerable livestock communities in Sub-Saharan Africa.

Respect for Cultures & Communities

Zoetis has taken actions to protect cultural sites by volunteering at the Willowwood Arboretum in Chester Township, New Jersey.

The company has no reported cultural appropriation incidents.

Safe & Smart Tech

Zoetis demonstrates a strong commitment to regulatory compliance, actively navigating global data privacy laws

and ensuring adherence to robust privacy and security protocols . The company has implemented a comprehensive cybersecurity governance program aligned with the NIST Framework and conducts annual ethical phishing campaigns and cyber exercises . A Privacy Center and Privacy Office work across business functions to protect collected data and ensure compliance with legal and regulatory requirements . Additionally, a compliance hotline and 'Safe to Say' program are in place to report concerns .

Zero Waste & Sustainable Products

Zoetis achieved a waste diversion rate of 78.62% in 2024, diverting 22,779 metric tons of waste from landfill.

The company demonstrates excellent hazardous waste management, achieving an 80.49% hazardous waste diversion rate in 2024. This is supported by robust risk assessments at manufacturing sites and key suppliers, on-site waste treatment, waste destruction, and an ambitious program of hazardous waste reduction projects at three top waste-generating sites. Zoetis has implemented numerous waste reduction initiatives, including a 22.3% reduction in non-hazardous waste sent to landfill in 2024 (803 metric tons compared to 2023). Other initiatives include the co-process recycling of 55 tonnes of waste solvent in Brazil in 2021, an 8.0 metric ton annual reduction in PVC plastic use by replacing vaccine packaging with paperboard, and the replacement of single-use with reusable pallets in Spain. The company also conducts robust risk assessments at key suppliers regarding API and manufacturing waste streams and surveyed top packaging vendors in 2021 on their sustainability packaging capabilities.